SG11201401563SA - Etanercept formulations stabilized with metal ions - Google Patents

Etanercept formulations stabilized with metal ions

Info

Publication number
SG11201401563SA
SG11201401563SA SG11201401563SA SG11201401563SA SG11201401563SA SG 11201401563S A SG11201401563S A SG 11201401563SA SG 11201401563S A SG11201401563S A SG 11201401563SA SG 11201401563S A SG11201401563S A SG 11201401563SA SG 11201401563S A SG11201401563S A SG 11201401563SA
Authority
SG
Singapore
Prior art keywords
metal ions
etanercept formulations
formulations stabilized
stabilized
etanercept
Prior art date
Application number
SG11201401563SA
Other languages
English (en)
Inventor
Mark Manning
Brian Murphy
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of SG11201401563SA publication Critical patent/SG11201401563SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
SG11201401563SA 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions SG11201401563SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060739 WO2013059406A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Publications (1)

Publication Number Publication Date
SG11201401563SA true SG11201401563SA (en) 2014-09-26

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
SG11201401563SA SG11201401563SA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols

Family Applications After (5)

Application Number Title Priority Date Filing Date
SG11201401576WA SG11201401576WA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with amino acids
SG11201401567YA SG11201401567YA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with meglumine
SG11201401519RA SG11201401519RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with xylitol
SG11201401562RA SG11201401562RA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with sodium chloride
SG11201401517VA SG11201401517VA (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with combinations of sugars and polyols

Country Status (28)

Country Link
US (21) US9393305B2 (enrdf_load_stackoverflow)
EP (6) EP2768535A4 (enrdf_load_stackoverflow)
JP (6) JP6110393B2 (enrdf_load_stackoverflow)
KR (7) KR20140091707A (enrdf_load_stackoverflow)
CN (6) CN103998060B (enrdf_load_stackoverflow)
AR (6) AR088460A1 (enrdf_load_stackoverflow)
AU (6) AU2012326084B2 (enrdf_load_stackoverflow)
BR (6) BR112014009131A8 (enrdf_load_stackoverflow)
CA (6) CA2851639C (enrdf_load_stackoverflow)
CY (1) CY1121843T1 (enrdf_load_stackoverflow)
DK (1) DK2768525T3 (enrdf_load_stackoverflow)
EA (6) EA025663B1 (enrdf_load_stackoverflow)
ES (1) ES2734070T3 (enrdf_load_stackoverflow)
HK (3) HK1200718A1 (enrdf_load_stackoverflow)
HR (1) HRP20191215T1 (enrdf_load_stackoverflow)
HU (1) HUE045624T2 (enrdf_load_stackoverflow)
IL (6) IL231828A0 (enrdf_load_stackoverflow)
IN (3) IN2014CN02527A (enrdf_load_stackoverflow)
LT (1) LT2768525T (enrdf_load_stackoverflow)
MX (7) MX2014004728A (enrdf_load_stackoverflow)
PL (1) PL2768525T3 (enrdf_load_stackoverflow)
PT (1) PT2768525T (enrdf_load_stackoverflow)
RS (1) RS59179B1 (enrdf_load_stackoverflow)
SG (6) SG11201401563SA (enrdf_load_stackoverflow)
SI (1) SI2768525T1 (enrdf_load_stackoverflow)
SM (1) SMT201900422T1 (enrdf_load_stackoverflow)
TW (6) TWI644681B (enrdf_load_stackoverflow)
WO (6) WO2013059406A1 (enrdf_load_stackoverflow)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080031684A (ko) 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
CA2851639C (en) * 2011-10-18 2020-12-29 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
BR112015000203A2 (pt) * 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
ES2657377T3 (es) * 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
AU2014261477A1 (en) * 2013-05-02 2015-11-19 Mabxience, S.A. Alternative formulations for TNFR: Fc fusion polypeptides
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
HRP20211371T1 (hr) * 2013-10-24 2021-11-26 Astrazeneca Ab Stabilne, vodene formulacije protutijela
US9700595B2 (en) 2013-11-29 2017-07-11 Ares Trading Sa Liquid formulation of a fusion protein comprising TNFR and Fc region
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
AU2015371381A1 (en) 2014-12-22 2017-07-20 Ares Trading S.A. Liquid pharmaceutical composition
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
EP3241849A4 (en) * 2014-12-31 2018-06-20 LG Chem, Ltd. Method for producing tnfr-fc fusion protein containing target content of impurities
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
JPWO2017179683A1 (ja) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
EP3533441A4 (en) * 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
MX2020005630A (es) * 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.
IL275238B2 (en) * 2017-12-22 2023-12-01 Samsung Bioepis Co Ltd Liquid composition comprising vegf antagonist
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
KR20220122993A (ko) * 2019-11-26 2022-09-05 코메라 라이프 사이언시스, 인코포레이티드 바이오폴리머 제형을 위한 부형제 화합물
EP4294371A1 (en) 2021-02-17 2023-12-27 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
KR100232688B1 (ko) 1992-09-15 1999-12-01 스코트 쥐. 홀퀴스트 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
CA2399436A1 (en) 2000-02-10 2001-08-16 Loran Marie Killar Method of treating or inhibiting cellular injury or cell death
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
WO2003102013A2 (en) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Methods and compositions for production of recombinant peptides
HUE031630T2 (en) * 2002-02-27 2017-07-28 Immunex Corp Stabilized TNFR-Fc containing arginine
PL213501B1 (pl) * 2003-02-28 2013-03-29 Ares Trading Sa Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
BRPI0413197A (pt) 2003-08-01 2006-10-03 Amgen Inc cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
AP2287A (en) 2003-10-14 2011-10-31 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
WO2005082377A1 (ja) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
KR101050585B1 (ko) 2004-03-05 2011-07-19 디에스엠 아이피 어셋츠 비.브이. 연속식 살포 및 교호 접선 흐름에 의한 세포 배양 방법
US20070196364A1 (en) * 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
KR20080031684A (ko) * 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
RS53127B2 (sr) 2005-12-20 2022-06-30 Bristol Myers Squibb Co Stabilne formulacije proteina
AU2006330858A1 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
GEP20135917B (en) * 2006-03-17 2013-09-10 Biogen Idec Inc Stabilized polypeptide compositions
EP1996076A2 (en) 2006-03-21 2008-12-03 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
EP2021030A2 (en) 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
CN103540575A (zh) * 2006-08-01 2014-01-29 奇尼塔二有限责任公司 医药制造方法
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
TW200833357A (en) * 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
LT2170390T (lt) * 2007-06-14 2019-01-10 Biogen Ma Inc. Natalizumabo antikūnų kompozicijos
EP2231175A4 (en) * 2007-11-30 2014-07-16 Abbvie Inc PROTEIN FORMULATIONS AND MANUFACTURING METHOD
CN101969929B (zh) * 2008-01-15 2014-07-30 Abbvie德国有限责任两合公司 粉末状蛋白质组合物及其制备方法
JP2011514895A (ja) 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
AU2010282733B2 (en) 2009-08-11 2016-07-14 Genentech, Inc. Production of proteins in glutamine-free cell culture media
US20120208986A1 (en) 2009-10-20 2012-08-16 Wenger Marc D Use of mixed mode chromatography for the capture and purification of basic antibody products
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
WO2011134920A1 (en) 2010-04-26 2011-11-03 Novartis Ag Improved cell culture medium
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
CA2807895A1 (en) 2010-08-31 2012-03-08 Friesland Brands B.V. Culture medium for eukaryotic cells
MX344268B (es) 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
CA2833427C (en) * 2011-04-20 2019-09-24 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein tnfr:fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2726081A4 (en) 2011-06-29 2015-04-15 Insite Vision Inc METHOD FOR TREATING RECURRING MIBOMEDE DISEASE AND REDUCING THE FREQUENCY FROM THEIR RECURRENCE
CN107988166B (zh) 2011-07-01 2022-03-15 美国安进公司 哺乳动物细胞培养
US10995130B2 (en) 2011-07-01 2021-05-04 Biogen Ma Inc. Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
KR101454316B1 (ko) 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
CA2851639C (en) * 2011-10-18 2020-12-29 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
ES2657377T3 (es) 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento

Also Published As

Publication number Publication date
TW201325609A (zh) 2013-07-01
WO2013059410A1 (en) 2013-04-25
US10376588B2 (en) 2019-08-13
BR112014009131A8 (pt) 2017-06-20
US20130108633A1 (en) 2013-05-02
US9770510B2 (en) 2017-09-26
EP2768531A4 (en) 2015-03-11
US9943601B2 (en) 2018-04-17
WO2013059406A1 (en) 2013-04-25
EP2768535A1 (en) 2014-08-27
AR088379A1 (es) 2014-05-28
BR112014009146A2 (pt) 2017-06-13
KR20140091706A (ko) 2014-07-22
US20130101640A1 (en) 2013-04-25
BR112014009087A2 (pt) 2017-04-18
US20190184017A1 (en) 2019-06-20
US20180028668A1 (en) 2018-02-01
MX2014004732A (es) 2015-05-15
US10772963B2 (en) 2020-09-15
US20190290768A1 (en) 2019-09-26
CA2851635A1 (en) 2013-04-25
AU2012326080A1 (en) 2014-04-24
BR112014009022A2 (pt) 2017-05-02
TW201325611A (zh) 2013-07-01
US20190314499A1 (en) 2019-10-17
AU2012326080B2 (en) 2017-02-16
EP2768532A1 (en) 2014-08-27
JP2014530862A (ja) 2014-11-20
MX2014004725A (es) 2015-02-05
KR20200008021A (ko) 2020-01-22
TW201325610A (zh) 2013-07-01
JP6220789B2 (ja) 2017-10-25
JP6104922B2 (ja) 2017-03-29
MX2014004728A (es) 2015-05-15
EA201490815A1 (ru) 2014-09-30
AR088381A1 (es) 2014-05-28
KR102068462B1 (ko) 2020-01-22
US20130101584A1 (en) 2013-04-25
AU2012326171B2 (en) 2017-03-09
IN2014CN02592A (enrdf_load_stackoverflow) 2015-09-04
US11129876B2 (en) 2021-09-28
US20190216930A1 (en) 2019-07-18
EA026410B1 (ru) 2017-04-28
AU2012326171A1 (en) 2014-04-24
EA201490801A1 (ru) 2014-09-30
SG11201401562RA (en) 2014-09-26
US20190314500A1 (en) 2019-10-17
JP6110393B2 (ja) 2017-04-05
AU2012326084A1 (en) 2014-04-17
CN104010658A (zh) 2014-08-27
PT2768525T (pt) 2019-07-17
US20160317667A1 (en) 2016-11-03
DK2768525T3 (da) 2019-07-22
EP2768533A1 (en) 2014-08-27
SG11201401576WA (en) 2014-10-30
US20190290767A1 (en) 2019-09-26
IL231826A0 (en) 2014-05-28
HK1200721A1 (en) 2015-08-14
WO2013059407A1 (en) 2013-04-25
EA027325B1 (ru) 2017-07-31
US10980885B2 (en) 2021-04-20
IN2014CN02591A (enrdf_load_stackoverflow) 2015-06-26
CA2851646A1 (en) 2013-04-25
AR088383A1 (es) 2014-05-28
TW201325606A (zh) 2013-07-01
US20130108632A1 (en) 2013-05-02
EA201490817A1 (ru) 2014-09-30
EA201490803A1 (ru) 2014-09-30
US20200405865A1 (en) 2020-12-31
TW201325608A (zh) 2013-07-01
TWI644681B (zh) 2018-12-21
CN103998061A (zh) 2014-08-20
BR112014009073A2 (pt) 2017-05-09
CA2851628A1 (en) 2013-04-25
AU2012326170B2 (en) 2016-12-22
HK1200722A1 (en) 2015-08-14
KR20140083037A (ko) 2014-07-03
IL231824A0 (en) 2014-05-28
TWI619504B (zh) 2018-04-01
ES2734070T3 (es) 2019-12-04
KR20140097184A (ko) 2014-08-06
KR102163150B1 (ko) 2020-10-08
EA028520B1 (ru) 2017-11-30
JP6113176B2 (ja) 2017-04-12
BR112014009031A2 (pt) 2017-05-09
IL231825A0 (en) 2014-05-28
WO2013059408A1 (en) 2013-04-25
US10888619B2 (en) 2021-01-12
HRP20191215T1 (hr) 2019-10-04
MX2019009176A (es) 2019-10-07
EP2768525A1 (en) 2014-08-27
IL231828A0 (en) 2014-05-28
MX2014004734A (es) 2015-05-15
AR088382A1 (es) 2014-05-28
AU2012326084B2 (en) 2016-12-15
AR088460A1 (es) 2014-06-11
JP2014530256A (ja) 2014-11-17
US20180125982A1 (en) 2018-05-10
SG11201401567YA (en) 2014-07-30
HK1200718A1 (en) 2015-08-14
MX2014004733A (es) 2015-05-15
MX367054B (es) 2019-08-02
EA201490802A1 (ru) 2014-08-29
US20190298837A1 (en) 2019-10-03
EP2768533A4 (en) 2015-03-11
AU2012326168A1 (en) 2014-04-24
JP2014530254A (ja) 2014-11-17
HUE045624T2 (hu) 2020-01-28
CN104011073A (zh) 2014-08-27
AU2012326082A1 (en) 2014-04-24
KR20140091705A (ko) 2014-07-22
US20160199489A1 (en) 2016-07-14
IN2014CN02527A (enrdf_load_stackoverflow) 2015-06-26
BR112014009146A8 (pt) 2017-06-20
EP2768525A4 (en) 2015-07-15
PL2768525T3 (pl) 2019-10-31
CN103998060A (zh) 2014-08-20
EA201490804A1 (ru) 2014-09-30
CN104010657A (zh) 2014-08-27
EA025663B1 (ru) 2017-01-30
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
EP2768531A1 (en) 2014-08-27
EA025267B1 (ru) 2016-12-30
AU2012326168B2 (en) 2016-12-15
US10213508B2 (en) 2019-02-26
IL231827A0 (en) 2014-05-28
TWI595883B (zh) 2017-08-21
TW201325607A (zh) 2013-07-01
SMT201900422T1 (it) 2019-09-09
US9801942B2 (en) 2017-10-31
MX2014004726A (es) 2015-05-15
SG11201401517VA (en) 2014-09-26
CA2851639A1 (en) 2013-04-25
US20180193463A1 (en) 2018-07-12
HK1200720A1 (en) 2015-08-14
JP6199298B2 (ja) 2017-09-20
EP2768854A1 (en) 2014-08-27
CA2851639C (en) 2020-12-29
HK1200851A1 (en) 2015-08-14
EP2768525B1 (en) 2019-06-19
JP2014530864A (ja) 2014-11-20
SG11201401519RA (en) 2014-07-30
EP2768854A4 (en) 2015-03-11
US10987405B2 (en) 2021-04-27
IL231829A0 (en) 2014-05-28
EP2768535A4 (en) 2015-03-11
SI2768525T1 (sl) 2019-10-30
US20190290765A1 (en) 2019-09-26
EP2768532A4 (en) 2015-03-11
JP2014530863A (ja) 2014-11-20
CY1121843T1 (el) 2020-07-31
CA2851651A1 (en) 2013-04-25
CA2851642A1 (en) 2013-04-25
JP2014530255A (ja) 2014-11-17
CN104011073B (zh) 2017-08-25
JP6220788B2 (ja) 2017-10-25
WO2013059412A1 (en) 2013-04-25
AU2012326082B2 (en) 2016-12-15
AR088380A1 (es) 2014-05-28
AU2012326170A1 (en) 2014-04-24
LT2768525T (lt) 2019-09-25
HK1200719A1 (en) 2015-08-14
KR20140091707A (ko) 2014-07-22
US10980884B2 (en) 2021-04-20
CN104010654B (zh) 2017-10-27
KR20140079491A (ko) 2014-06-26
BR112014009131A2 (pt) 2017-06-13
US20190314498A1 (en) 2019-10-17
US9302002B2 (en) 2016-04-05
US20190290766A1 (en) 2019-09-26
CN103998060B (zh) 2016-12-21
CN104010654A (zh) 2014-08-27
US11135267B2 (en) 2021-10-05
RS59179B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
IL231825A0 (en) Formulations of ethenecept stabilized with metal ions
ZA201400692B (en) Stabilized subtilisin composition
IL227758A0 (en) Copper-nickel-zinc-manganese alloy
ZA201308893B (en) Low water metal ion dentifrice
ZA201402914B (en) Hard metal composition
IL239125A0 (en) Preparations containing a stable metal ion
ZA201303555B (en) Metal ion nanoclusters
IL230217B (en) New mutations ecd–r17–il
IL214102A0 (en) Wide area neutralizer
GB201103569D0 (en) Mutants
EP2691106A4 (en) ANTIVIRAL COMPOSITION
GB201103964D0 (en) Composition
GB201115211D0 (en) Composition
GB201116416D0 (en) Composition
GB201113058D0 (en) Metal conduit assemblies
GB201106733D0 (en) Metal treatment
GB201100605D0 (en) Metal treatment
PL395179A1 (pl) Specyficzna sekwencyjnie rybonukleaza H
PH32011001047S1 (en) Metal plate
PH32011001048S1 (en) Metal plate
PH32011001049S1 (en) Metal plate
PH32011001046S1 (en) Metal plate
EP2908969A4 (en) METHOD OF INJECTING METAL ALLOYS
GB201116817D0 (en) Composition
GB201116433D0 (en) Composition